Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 9/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.80 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.80 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.80 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.80 |
| ▸ | GLA | P06280 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | GABRP | O00591 | 1/20 | 0.55 |
| ▸ | GABRD | O14764 | 1/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alfadolone SCHEMBL2512102 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL14525649 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL30555809 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL17223283 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL20075616 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL24023700 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL28333104 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL57673 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL21614058 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 | |
| Alfadolone SCHEMBL750779 | 1.00 | G6PD (1.00) | G6PDGABRA1GABRB2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11975073-B2 | Lipid prodrugs of neurosteroids | PURETECH LYT, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2022-12-15 | — | — | US | disclosed |
| EP-4100017-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PureTech LYT, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20210355157-A1 | NEUROACTIVE STEROIDS AND METHODS OF PREPARATION | DRAWBRIDGE PHARMACEUTICALS PTY LTD (AU) | 2021-11-18 | — | — | US | disclosed |
| US-20210300962-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2021159021-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20140309186-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION | 2014-10-16 | — | — | US | disclosed |
| US-20110246081-A1 | Metabolomics-Based Identification of Disease-Causing Agents | GEORGIA TECH RESEARCH CORPORATION (US) | 2011-10-06 | — | — | US | disclosed |
| US-5763431-A | MODIFIED NEUROACTIVE STEROID | JACKSON MEYER B (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1990005528-A2 | ANTI-THROMBOTIC STEROIDS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1990-05-31 | — | — | WO | disclosed |
| US-4391803-A | STEROID BLEND | HEPAR INDUSTRIES (US) | 1983-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | G6PD 1035/4885GABRA1 2097/4885GABRB2 2004/4885 |
| US-20210300962-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | CYP21A2, CYP46A1, CYP17A1 | G6PD 861/4885GABRA1 1454/4885GABRB2 1504/4885 |
| US-20220395513-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | G6PD 1035/4885GABRA1 2097/4885GABRB2 2004/4885 |
| US-20210355157-A1 | NEUROACTIVE STEROIDS AND METHODS OF PREPARATION | GAP43, CHRNB4, ADRA2C | G6PD 3145/4885GABRA1 63/4885GABRB2 100/4885 |
| US-11975073-B2 | Lipid prodrugs of neurosteroids | CYP21A2, CYP46A1, CYP17A1 | G6PD 1035/4885GABRA1 2097/4885GABRB2 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.